Sponsored
Health

Novartis And Medicines For Malaria Venture Report Positive Results For Phase 2b

Sponsored
Sponsored

Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria; In the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine met the primary study objective; The positive Phase 2b results for the next generation antimalarial therapy support continued development of the combination.

As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a new non-artemisinin combination in a Phase 2b study.

The study tested ganaplacide, a novel agent with an entirely new mechanism of action, in combination with a new formulation of lumefantrine that is optimised for once daily dosing. This combination has the potential not only to clear malaria infection, including artemisinin resistant strains, but also to block the transmission of the malaria parasite.

This Phase 2b study was an open label randomized controlled study conducted in two parts and which enrolled more than 500 patients with acute uncomplicated malaria due to Plasmodium falciparum infection. After successful evaluation of the treatment in 349 patients older than 12 years in Part A of the study, Part B enrolled 175 patients under 12 years of age in seven countries that suffer from endemic malaria (Burkina Faso, Côte d’Ivoire, Gabon, Kenya, Mali, Uganda and India).

The ganaplacide/lumefantrine solid dispersion formulation combination met the primary objective in Part B of the study in children with acute uncomplicated malaria. The primary objective of adequate clinical and parasitological response (ACPR) at Day 29 with polymerase chain reaction (PCR) correction was considered to be met if the lower limit of the 2-sided 95% exact confidence interval for PCR corrected ACPR) rate was greater than 80%.

In children with acute uncomplicated malaria, response to treatment with ganaplacide/lumefantrine was similar to the rate observed in patients who received artemether-lumefantrine control therapy. Ganaplacide/lumefantrine also demonstrated similar median parasite-clearing times compared to the control therapy. The combination of ganaplacide/lumefantrine solid dispersion formulation was generally well tolerated in the children. 

“The world needs a diversified pipeline of anti-malarial medicines, especially as we are faced with emerging resistance to current treatments,” said Sujata Vaidyanathan, Head Global Health Development Unit, Novartis. “These results are definitely good news, but much more work remains. In a world where a child dies of malaria every two minutes [1], we must continue to accelerate the progress in the development of new tools to save lives.”



“This is a truly exciting step forward in the development of next-generation antimalarials,” said Dr David Reddy, CEO of MMV. “With this phase 2b data we remain cautiously optimistic that ganaplacide/lumefantrine could one day be saving the lives of those at greatest risk of malaria – young children. MMV is proud to have partnered with Novartis in this project right from the discovery of the compound through to its clinical development and look forward to the next steps. We congratulate Novartis for the timely completion of this study given the additional challenges posed by COVID-19, and also would particularly like to thank the investigators, caregivers, patients and their families.”

The study was led by Novartis with scientific and financial support from MMV and their donors. The ganaplacide/lumefantrine solid dispersion formulation is also included in the WANECAM2 consortium activities funded by the European & Developing Countries Clinical Trials Partnership (EDCTP) that supports capacity building in Africa.    

These positive results support the future progression of the combination in patients with acute uncomplicated malaria.  

The results are timely given the recent publication of a study in the New England Journal of Medicine [2] that found decreased sensitivity to artemisinin  in Uganda, a year after the publication of similar research in Rwanda.

Plasmodium falciparum malaria is primarily treated with artemisinin combination therapies (ACTs) such as artemether-lumefantrine. ACTs are still highly effective and well tolerated.  Novartis introduced the first fixed-dose combination ACT in 1999 and has since delivered more than 1 billion courses of antimalarial treatment, largely at no profit. However, the increased observation of parasites with a slower response to artemisinin in Africa points to an increasingly urgent need to develop a new non-artemisinin class of anti-malarials to avoid a return to the high levels of childhood mortality last seen in the 1990s.

Sponsored
Alinnor Arinze

Recent Posts

2027: Senator Adeola Warns Against Attacks On APC Candidates And Assets

Senator Solomon Olamilekan Adeola, the All Progressives Congress governorship candidate, popularly known as Yayi, has…

6 hours ago

Comrade Dauda Hails Dangote Group’s First Electric Truck, Commends Push For Sustainable Industrialisation

ADEOLA OGUNLADE  The Executive Chairman of Ikeja Local Government, Comrade Akeem Olalekan Dauda (AKOD), has…

6 hours ago

ABATSECO Joins Over 4,000 Lagos Public Servants At Fitness Walk, Reaffirms Commitment To PBAT–KOH 2027 Agenda

The Asiwaju Bola Ahmed Tinubu Continuation Group (ABATSECO) has reaffirmed its commitment to grassroots mobilisation,…

6 hours ago

Gov Soludo To Politicians: Keep Off Places Of Worship — Hails Odumeje As A Partner In Cleansing Anambra

CHRISTIAN ABURIME "Politicians, keep off places of worship! I don't do politics in the house…

7 hours ago

UBA Intensifies Fight Against Phishing, Scam as 2026 Fraud Awareness Week Begins

Africa's Global Bank, United Bank for Africa (UBA) Plc, has stepped up its fight against…

7 hours ago

Oyo City Boy Movement: “Why We Suspended Erring Members, How N50m Mobilisation Fund Was Utilised”

The Oyo State chapter of the City Boy Movement has explained the reasons behind the…

7 hours ago
Sponsored